Drug Profile
Research programme: genetic cardiomyopathy therapeutics - MyoKardia
Latest Information Update: 25 Nov 2020
Price :
$50
*
At a glance
- Originator MyoKardia
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action Muscle protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiomyopathies
Most Recent Events
- 17 Nov 2020 MyoKardia has been acquired by Bristol-Myers Squibb
- 28 Jul 2019 No recent reports of development identified for research development in Cardiomyopathies in USA
- 16 Jul 2016 No recent reports of development identified for research development in Cardiomyopathy in USA